An open label study to assess the effect of FOLFIRI [fluorouracil, folinic acid, irinotecan] plus Avastin [bevacizumab] and cetuximab on progression-free survival in patients with previously untreated metastatic colorectal cancer.

Trial Profile

An open label study to assess the effect of FOLFIRI [fluorouracil, folinic acid, irinotecan] plus Avastin [bevacizumab] and cetuximab on progression-free survival in patients with previously untreated metastatic colorectal cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Aug 2016 Status changed from discontinued to withdrawn prior to enrolment.
    • 18 Jun 2008 Status changed from initiated to discontinued according to Roche.
    • 21 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top